Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Fig. 2

Log-logistic PFS curves used in model base case. KM, Kaplan–Meier; PFS, progression-free survival; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us